COMMUNIQUÉS West-GlobeNewswire

Resonant Inc. to Introduce New 5G RF Filter Breakthrough at the 2018 IEEE International Ultrasonics Symposium in Kobe, Japan, on October 24th

09/10/2018 - 13:05

GOLETA, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today announced [...]

IMV Inc. to Present at Upcoming Investor Conferences

09/10/2018 - 13:05

DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial [...]

Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

09/10/2018 - 13:00

Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation ( [...]

Radient Technologies Inc. receives Controlled Drugs and Substances Licence for its Manufacturing Facility

09/10/2018 - 13:00

EDMONTON, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce that it has received its Controlled Drugs and Substances Licence, [...]

Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress

09/10/2018 - 12:45

STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that [...]

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

09/10/2018 - 12:30

Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA ® (by Merck & Co., Inc.) or YERVOY ® (by Bristol-Myers Squibb Company) in advanced breast cancer. KEYTRUDA ® and YERVOY ® have been highly [...]

ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress

09/10/2018 - 12:15

SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan [...]

Canopy Rivers Announces Proposed Restructuring of Investment in TerrAscend

09/10/2018 - 12:00

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ”) (TSXV: RIV) is pleased to announce it has entered into an arrangement [...]

Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress

09/10/2018 - 12:00

BERKELEY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's [...]

Transactions in relation to share buyback program

09/10/2018 - 09:48

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method

09/10/2018 - 08:40

AroCell AB announces today that a second abstract has been accepted by ISOBM ( International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany November 24-27, 2018. [...]

CellaVision AB pesents the third quarter 2018 on October 23 at 11:00 CET

09/10/2018 - 08:21

CellaVision presents the third quarter 2018 on October 23 at 11:00 CET The information was submitted to the public on October 9, 2018 at 8:20 CET CellaVision AB (publ) will publish the interim report for the third [...]

Eurobio Scientific : 2018 MID-YEAR RESULTS

09/10/2018 - 08:01

2018 MID-YEAR RESULTS Significantly positive EBITDA at +€2.4M A first time in the Group History, thanks to the strategy implemented mid 2017 Paris, October 9, 2018 - 8.00 pm Eurobio Scientific (FR0013240934, ALERS, [...]

Eurobio Scientific : RESULTATS SEMESTRIELS 2018

09/10/2018 - 08:01

RESULTATS SEMESTRIELS 2018 EBITDA significativement positif à +2,4 M€ Une première dans l'histoire du Groupe, fruit de la stratégie mise en place mi 2017 Paris, le 9 octobre 2018 - 8h00 Eurobio Scientific (FR0013240934 [...]

Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

09/10/2018 - 07:01

PRESS RELEASE : REGULATED INFORMATION 9 October 2018, 07:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 9 October 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

09/10/2018 - 07:00

October 9, 2018 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

CytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting

09/10/2018 - 01:24

Update from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab SOUTH SAN FRANCISCO, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX [...]

Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at ESMO 2018 Congress

09/10/2018 - 00:51

Media Release Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer Copenhagen, Denmark and BOTHELL, Wash., October 9, 2018 – Genmab A/S (Nasdaq Copenhagen [...]

Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress

09/10/2018 - 00:10

PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about [...]